Liu JF, et al. - Researchers investigated the activity of combined nivolumab and bevacizumab in women with relapsed epithelial ovarian cancer via conducting a single-arm, phase 2 trial of 38 women between February 8, 2017, and December 29, 2017, at 2 sites in the United States. Participants had disease recurrence within 12 months of their last platinum-based therapy and had received between 1 and 3 lines of prior therapy. Intravenous nivolumab and intravenous bevacizumab were provided once every 2 weeks to the participants. Among participants, 18 had platinum-resistant and 20 had platinum-sensitive disease. An objective confirmed response was noted in 28.9% after combination therapy with nivolumab and bevacizumab by Response Evaluation Criteria in Solid Tumors 1.1, reaching the threshold for further investigation of the combination in this setting. Platinum-sensitive patients had a response rate of 40.0% and platinum-resistant patients had a response rate of 16.7%.